Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator?
Duke Clinical Research Institute, Durham, NC, USA. Electronic address: alkha001@mc.duke.edu.
Sana M
SM
Al-Khatib
University of Washington, Seattle, WA, USA.
Joo Y
JY
Han
Duke Clinical Research Institute, Durham, NC, USA.
Rex
R
Edwards
University of Washington, Seattle, WA, USA.
Gust H
GH
Bardy
Columbia University, New York, NY, USA.
J Thomas
JT
Bigger
Beth Israel Deaconess Medical Center, Boston, MA, USA.
Alfred E
AE
Buxton
I.R.C.C.S. Policlinico San Donato, Milan, Italy.
Riccardo
R
Cappato
University of Toronto, Toronto, ON, Canada.
Paul
P
Dorian
University of Washington, Seattle, WA, USA.
Al
A
Hallstrom
Northwestern Feinberg School of Medicine, Chicago, IL, USA.
Alan H
AH
Kadish
University of Washington, Seattle, WA, USA.
Peter J
PJ
Kudenchuk
Duke Clinical Research Institute, Durham, NC, USA.
Kerry L
KL
Lee
Duke Clinical Research Institute, Durham, NC, USA.
Daniel B
DB
Mark
University of Rochester, Rochester, NY, USA.
Arthur J
AJ
Moss
Columbia University, New York, NY, USA.
Richard
R
Steinman
University of Washington, Seattle, WA, USA.
Lurdes Y T
LY
Inoue
Duke Clinical Research Institute, Durham, NC, USA.
Gillian D
GD
Sanders
D000368:Aged; D016757:Death, Sudden, Cardiac / Q000517:prevention & control*; D017147:Defibrillators, Implantable; D005260:Female; D054143:Heart Failure, Systolic / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011322:Primary Prevention; D016032:Randomized Controlled Trials as Topic; D013318:Stroke Volume / Q000502:physiology*; D016896:Treatment Outcome
Ejection fraction; Implantable cardioverter defibrillator; Survival